There’s no better due diligence in the psychoactive drug space than Health Canada. Loads of pharma companies have investor decks that promise they’ll one day be in the psychedelics…
Ketamine
A few weeks back, in what has become a seminal Equity.Guru piece about the quickly legalizing safe supply drug space, I tore into PharmaDrug (PHRX.C), which was lurching into…
We have some 29 companies on our watchlist, all in a variety of sectors, that we’re covering at any one time. Some are clients, some not, some are on…
I recently listened to a podcast episode of Search Engine with PJ Vogt, and I REALLY got into it. The episode was titled, “Why are drug dealers putting fentanyl…
The psychedelics sector is looking ready for a reversal. We are just waiting for the breakout confirmation. Earlier this week, we discussed how the bottom is in for cannabis…
Back in October, Zuckerberg, seeing plunging user numbers and fading growth, desperately renamed Facebook, once the world’s foremost purveyor of misinformation and unethical aggregator of personal data, to Meta,…
Filament Health (FH.NE) has released two new press releases since the last time I covered the company back in mid January 2022. Filament Health Corp. operates as a natural psychedelic…
We’re not out of the woods yet, but the major indices are turning green again and psychedelics, recently a relative investment pariah, are getting some love from investors. The…
Another Psychedelics article, and once again I try to answer the question: is it time to buy the dips in Psychedelics. My views remain the same. In this market,…
Health Canada stepped up to the plate back in December with a Notice of Intent to amend the Food and Drug Regulations and the Narcotic Control Regulations to restore…